According to a report of the Expert Review of Clinical Pharmacology Journal, a single tablet combination of Amlodipine besylate and Celecoxib with the advantage of reduced cost, less likelihood of dosage-related issues, and increased compliance presents as a promising therapy for patients with hypertension and osteoarthritis. The patients with osteoarthritis frequently suffer from several cardiovascular comorbidities such as hypertension.

Recent studies approved that the combination of a nonsteroidal anti-inflammatory drug (Celecoxib) and a calcium channel blocker (Amlodipine besylate) is beneficial combinational medication for osteoarthritis. This analysis evaluated this combination impact among hypertensive patients with osteoarthritis. The data regarding the analysis were collected using research Methodology Filters. Along with the various advantages, the combined drug formula exhibited the systemic vasodilatation produced by the Amlodipine and anti-inflammatory properties induced by the Celecoxib.

Although, Celecoxib may induce a mutable degree of blood pressure rise and only a small clinical study has been directed before.